NATIONAL KIDNEY FOUNDATION ANNUAL SCIENTIFIC MEETING

National Kidney Foundation’s (NKF) Annual Scientific Meeting, November 13 to 15, 1992. Convention Center, Baltimore, MD, includes lectures, symposia and special programs on Pathogenesis of Diabetes, Benign Prostatic Hyperplasia, Adult Polycystic Kidney Disease, Hypertension, Renal Stone Disease, Glomerulonephritis, Renal Diagnostic Imaging, Reflux Nephropathy, Nutrition, and Dialysis Care. For additional information, please contact the National Kidney Foundation, 30 East 33rd Street, New York, NY 10016; (212) 889-2210; (800) 622-9010.

REPORT OF THE END-STAGE RENAL DISEASE DATA ADVISORY COMMITTEE 1991
END-STAGE RENAL DISEASE DATA ADVISORY COMMITTEE

CHAIRPERSON
Robert W. Schrier, M.D.
Denver, Colorado

MEMBERS
Clive O. Callender, M.D.
Washington, D.C.
Mardee W. Hagen
Salt Lake City, Utah
Alan R. Hull, M.D.
Dallas, Texas
Judith R. Lave, Ph.D.
Pittsburgh, Pennsylvania
Robert J. Rubin, M.D.
Washington, D.C.

EX OFFICIO
MEMBERS
Robert R. Antos, Ph.D.
Health Care Financing Administration
Kathleen A. Buto
Health Care Financing Administration
L. Earl Laurence
National Institute of Diabetes and Digestive and Kidney Diseases
Gary E. Striker, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases

STAFF
Ralph L. Bain, Ph.D.
Executive Secretary

Introduction
The charter of the End-Stage Renal Disease Data Advisory Committee as approved by Secretary of Health and Human Services, Louis W. Sullivan, M.D., defines the function of this Committee as follows: “The End-Stage Renal Disease Data Advisory Committee shall provide advice to the Secretary in the Department’s formulation of policies and procedures relevant to the management of the Department’s data collection and analysis efforts on End-Stage Renal Disease (ESRD). To this end, the Committee will consider and discuss ongoing and planned studies in this area and provide advice to the Secretary regarding their overall integration and coordination. In so doing, the Committee will provide advice to the Secretary regarding relevant biomedical research studies funded by the NIDDK, including the outcomes of experimental therapies for ESRD, and relevant studies funded by the HCFA on economic/cost-effectiveness/reimbursement issues related to ESRD.” On this basis, the Committee received testimony from the following 12 organizations: Institute of Medicine (IOM), Renal Physicians Association (RPA), American Society of Nephrology (ASN), Urban Institute, Scientific Advisory Committee of the U.S. Renal Data Systems (USRDS), United Network for Organ Sharing (UNOS), Agency for Health Care Policy and Research (AHCPR), Health Resources and Services Administration (HRSA), National Kidney and Urological Data Advisory Board (NKUDAB), National Kidney Foundation (NKF) Interagency Coordinating Com-